Peer-reviewed work published in the last few months. The full record lives on the Publications page.
Two high-throughput platforms measuring 25-hydroxyvitamin D on the same 1064 paired outpatient samples disagree enough to matter: the immunoassay flags deficiency in 546 samples against 312 for mass spectrometry, so the choice of platform, not the patient, decides a large share of the supplementation decisions.
Accepted abstracts and work in press, soonest first. Autumn 2026: four contributions across laboratory medicine, human genetics and medical imaging informatics.
A method comparison between chemiluminescent immunoassay and automated LC-MS/MS for 25-hydroxyvitamin D, quantifying how the choice of platform moves patients across the clinical thresholds for deficiency. The underlying study was published in Diagnostics on 9 August 2026.
A multi-agent system that applies the ACMG/AMP criteria to germline BRCA1/2 variants, validated against a molecular geneticist on 170 cases. Substantial agreement and full sensitivity on pathogenic variants, positioned as decision support rather than replacement.
Transcript-level evidence resolving a novel BRCA1 exon 15-18 duplication, supporting its reclassification as likely pathogenic where DNA analysis alone was inconclusive.
A retrospective multicentre evaluation of five open-source language models translating free-text Italian mammography reports into structured BI-RADS categories, including whether an ensemble improves on any single model.